Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

(2014) Julio Rosenstock et al.   DIABETES CARE

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

(2014) Bo Ahrén et al.   DIABETES CARE

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

(2014) Richard E Pratley et al.   Lancet Diabetes & Endocrinology

Canagliflozin: Improving diabetes by making urine sweet

(2013) M. VOUYIOUKLIS   CLEVELAND CLINIC JOURNAL OF MEDICINE

Standards of Medical Care in Diabetes--2014

(2013)   DIABETES CARE

Control of Glycemia and Cardiovascular Risk Factors in Patients With Type 2 Diabetes in Primary Care in Catalonia (Spain)

(2012) I. Vinagre et al.   DIABETES CARE

Pre-existing cardiovascular diseases and glycemic control in patients with type 2 diabetes mellitus in Europe: a matched cohort study

(2010) Alex Z Fu et al.   Cardiovascular Diabetology

Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?

(2010) Mikkel Christensen et al.   Current Diabetes Reports

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

(2010) D. J. Drucker et al.   DIABETES CARE

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

(2010) M. A. Nauck et al.   DIABETOLOGIA

Albiglutide

(2010) J. Rosenstock et al.   DRUGS OF THE FUTURE

Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects

(2009) M. A. Bush et al.   DIABETES OBESITY & METABOLISM

Emerging Concepts in the Pathophysiology of Type 2 Diabetes Mellitus

(2009) Prasanth N. Surampudi et al.   MOUNT SINAI JOURNAL OF MEDICINE

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes

(2008) Jessica E. Matthews et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM